Introduction: Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory diseases of unclear
etiology. There is evidence, that genetic, immunologic, and environmental factors
contribute to its pathology. Autoimmune oophoritis has been proposed as one of the
possible etiologies of diminished ovarian reserve. Pro-inflammatory cytokine - tumor
necrosis factor alpha (TNFα) is implicated in the pathogenesis of oophoritis and psoriasis.
Certolizumab is an anti-TNFα monoclonal antibody studied now in the treatment of psoriasis.
Here we present a case of a patient diagnosed with psoriasis, PsA and diminished ovarian
reserve, in which we observed normalization of ovarian reserve surrogates after treatment
with certolizumab. To our knowledge, it is a first such a case report in the literature.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Published online: August 06, 2019
Identification
Copyright
© 2019 Published by Elsevier Inc.
